MassBio Policy Update
MassBio continues to closely monitor legislative initiatives at both the state and federal level.
The Massachusetts Legislative session ended on July 31 – going right down to the wire. As reported in our last edition, MassBio has been working diligently on co-pay assistance legislation. Currently, Massachusetts is the only state in the country that does not allow consumers and patients to utilize rebates for medications and therapies and discounts provided by manufacturers. This impacts our member companies who want to implement programs they offer elsewhere here in Massachusetts. But more importantly, it is an issue of patient access. Why should we mandate all citizens to incur the significant cost of private health insurance yet then prohibit them saving on their out of pocket expenses? The House of Representatives agreed and unanimously passed the copay assistance measure. The Senate however did not act on the bill until the final hour of the session and added language that could not be accepted. We will continue to advocate for the bill during the informal session, and build on the success we had in this session to reintroduce it in January.
MassBio is hosting a luncheon forum for the gubernatorial candidates on Oct. 4 at the Boston Marriott Cambridge. The event, sponsored by Amgen and Abbott, will allow MassBio members to hear each candidate’s position on a number of issues of interest to the industry. Please look for more information in your mail and inbox.
On the federal level, we continue to monitor and advocate for the industry through the process of implementing the new healthcare law. We will be working with other organizations and stakeholders to ensure we establish a clear position and communicate any negative impact this new law may have on our industry and innovators.
Stay tuned for up-to-date resources and information on healthcare reform implementation.